Capricor Deramiocel Securities Fraud Class Action
Analysis based on 267 articles · First reported Aug 10, 2026 · Last updated Sep 22, 2026
The litigation and the underlying FDA disclosure event have already driven a roughly 64% single-day collapse in Capricor shares, and the pending class action keeps a material overhang on the stock and on sentiment toward clinical-stage biotechnology names with disputed statistical analysis plans. The extended PDUFA date to November 22, 2026 shifts the binary regulatory catalyst for Capricor further out, sustaining elevated volatility and headline risk for the sector.
Paragon Therapeutics, Inc. (NASDAQ: CAPR) and certain of its officers are defendants in a securities fraud class action pending in the United States — United States District Court for the Southern District of California, captioned Nkamga v. Paragon Therapeutics, Inc., et al., No. 26-cv-04385. The class period runs from December 17, 2025 to July 26, 2026. The complaint alleges that Capricor adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for its lead product candidate Deramiocel, a cell therapy for Duchenne muscular dystrophy, and that the United States — Food and Drug Administration had not agreed to those changes before Capricor resubmitted its Biologics License Application. On July 27, 2026, the FDA released briefing documents ahead of its July 29 advisory committee meeting stating that the final SAP version was not submitted for review prior to BLA submission and was not agreed upon, that the conversion of raw change to percent change and back was not scientifically justified, and that the benefit-risk assessment for Deramiocel appeared unfavorable in the absence of evidence of effectiveness. Capricor shares fell $12.70, or 64%, to close at $7.00 on July 27, 2026. On July 29, 2026 the advisory committee met and, according to Medscape, voted 9-3 that available evidence does not support efficacy of Deramiocel for DMD-associated cardiomyopathy; shares fell a further 36% to $4.19 on July 30, 2026. On August 24, 2026 Capricor announced that the FDA extended the PDUFA target action date for the Deramiocel BLA from August 22, 2026 to November 22, 2026, classifying the submission as a major amendment. Numerous law firms have issued notices reminding investors of the September 28, 2026 lead plaintiff deadline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard